Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines
Year: 2025
Type: preprint
Study design: Observational Study
Source: Research Square
Authors: Laurence Zitvogel, Agathe Carrier, Paolo Manghi, Carolina Alves Costa Silva, Imran Lahmar, Roxanne Birebent, Deborah Suissa, Caroline Laheurte, Gerty Schreibelt, Louis Lemant, Jean-Eudes FAHRNER, Eric de Sousa, Franck Berthier, Juliette Villemonteix, Mathieu Chevalier, Gianmarco Piccinno, Didier Hocquet, Isabelle Lebhar, Markus Maeurer, Sophie Caillat-Zucman, Guido Kroemer, Lisa Derosa, Odile Launay, Encouse Golden, Kalijn Bol, I. Jolanda M. De Vries, Olivier Adotévi, Nicola Segata, Silvia Formenti, Sebastian Kobold, Dietmar Pieper, Marius Vital, Antonio Santos-Peral, Magdalena Zaucha, María García-Bengoa, Julia Thorn-Seshold, Helen Stirling, Simon Rothenfusser, Valerio Iebba, Andrew Almonte, Nadim Ajami, Michael White, Pranoti Sahasrabhojane, Yasmine Hoballah, Jillian Losh, Carolyn DePinho, Eleonora Dondossola, Jennifer Wargo
Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Fondazione Edmund Mach, Inserm, Université Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Champalimaud Foundation, bioMérieux (France), Hôpital Saint-Louis, University of Trento, Université de Franche-Comté, Assistance Publique – Hôpitaux de Paris, Université Paris Cité, Sorbonne Paris Cité, Hôpital Cochin, Centre d'Investigation Clinique de Vaccinologie Cochin-Pasteur, Weill Cornell Medicine, LMU Klinikum, Ludwig-Maximilians-Universität München, Medizinische Hochschule Hannover, University of Trieste, The University of Texas MD Anderson Cancer Center
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: Bristol-Myers Squibb, Melanoma Research Alliance, Regeneron Pharmaceuticals, Celldex Therapeutics, Les Laboratories Pierre Fabre, European Commission, Deutsche Forschungsgemeinschaft, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, ZonMw, Bayerische Forschungsstiftung, Ludwig-Maximilians-Universität München, Deutsche Krebshilfe, Assistance publique-Hôpitaux de Paris, Zorginstituut Nederland, Servier, Hector Stiftung, Institut Servier, National Institutes of Health, Genentech, Weill Cornell Medical College, University of Texas MD Anderson Cancer Center, Stand Up To Cancer, HORIZON EUROPE Framework Programme, Elitenetzwerk Bayern, Helmholtz Zentrum München, National Cancer Institute, HORIZON EUROPE European Research Council
Awards: Define a lead candidate for clinical development of a novel T cell therapy, G111615301, G1468253849, G1809379011, G1901027039, G2576477382, Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response., G2902734143, TRR 237: NukleinsäureImmunität, G293715275, Mechanismen der Effektivität der Gelbfieber17DImpfung: Ein immunostruktureller Ansatz mit Blick auf die Entwicklung einer PanFlavivirus Vakzine, G3692162842, G3726397627, G4328076566, G434337789, G4963151808, Understanding the mechanism of Yellow Fever 17D vaccine efficacy: An immuno-structural approach towards the design of a Pan-flavivirus vaccine, G6209871035, Training Network for Optimizing Adoptive T cell Therapy of Cancer, G6736661663, G6803667113, Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design, G7135536653, Bispecific antibodies and T cell activating proteins against melanoma, G782482008, Cancer tailored next generation cellular therapies, Exploiting public metagenomic data to uncover cancer-microbiome relationships, G9000034222, G9000265501
OpenAlex ID: W4415623004